BLOG / 🇺🇸 United States / broad market · · daily

US SEC Filings Daily Market Digest — August 05, 2026

Daily USA Market Intelligence

By Gunpowder Editorial ·

23 high priority 27 medium priority 50 total filings analysed

Executive Summary

Today's digest (August 5, 2026) reveals a market bifurcated between strong top-line growth and mounting operational pressures. Revenue growth is a common theme, with 8 out of 10 reporting companies showing YoY increases, but margin compression and rising costs are eroding profitability for many.

A notable pattern is the prevalence of 'mixed' sentiment (12 of 18 filings with sentiment data), driven by non-recurring gains masking underlying operational challenges, as seen in ZipRecruiter, Schrodinger, and Honest Company. Capital allocation is aggressive, with significant M&A activity (Labcorp, Warner Music, Blue Bird) and share buybacks (Uber, ZipRecruiter), but this is straining balance sheets, as evidenced by declining cash positions at Labcorp and Iron Mountain. Insider activity is limited, but the Space-Eyes SPAC merger with Eric Trump's involvement is a high-profile event. The most critical developments include Verra Mobility's downward guidance revision, LegalZoom's workforce reduction and lowered outlook, and the transformative CRH acquisition of Arcosa, which collectively signal caution in specific end-markets despite overall economic resilience.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K · 10-Q · 13F · Form 4

Tracking the trend? Catch up on the prior US SEC Filings Daily Market Digest digest from August 04, 2026.

Investment Signals (12)

  • Warner Music Group ↓ (BULLISH)
    ▲

    Revenue grew 10% YoY, net income swung to $200M from a -$16M loss, and Recorded Music operating margin expanded 710 bps to 21.9%. Strong digital streaming growth (+9.4%) and aggressive catalog acquisitions ($505M in 9M) signal a bullish long-term strategy

  • Iron Mountain ↓
    ▲

    Revenue grew 18.5% YoY to $2.03B, with operating income up 43.7%. The company swung to a net profit of $101M from a -$45M loss. However, total debt rose to $17.35B and equity deficit deepened, making the growth story a leveraged bet [BULLISH/BEARISH]

  • Uber Technologies ↓ (BULLISH)
    ▲

    Q2 revenue grew 12% YoY to $14.2B, and net income surged 77% to $2.4B. The company repurchased $3.5B in stock in H1 2026, signaling strong confidence. However, H1 net income declined 15% vs H1 2025, and the tax provision swung to a $1.0B expense from a -$260M benefit

  • Digi International ↓ (BULLISH)
    ▲

    Revenue grew 29% YoY to $138.7M, net income rose 54%, and gross margins expanded 130 bps to 64.8%. The company reduced long-term debt by $51M, demonstrating strong operational and financial discipline

  • Warrior Met Coal ↓ (BULLISH)
    ▲

    Net income swung to $159.8M from a -$2.6M loss, with total revenues surging 62% to $968.3M. The turnaround is driven by a 63% increase in sales, indicating strong demand for met coal

  • ZipRecruiter ↓ (BEARISH)
    ▲

    Net income of $43.4M vs a -$9.5M loss, driven by a $59.3M gain on debt extinguishment. Revenue grew only 5.2%, and cash declined 31% to $129.7M. The core business is barely growing, and the profit is non-recurring

  • Schrodinger ↓ (BEARISH)
    ▲

    Net income of $5.975M vs a -$43.173M loss, but this was entirely due to a $45.9M gain on equity investments. Software revenue declined 9.7%, and operating cash flow turned deeply negative to -$48.9M from +$91.9M. The core business is deteriorating

  • Verra Mobility ↓ (BEARISH)
    ▲

    Revenue grew 12% YoY, but net income swung to a -$48.2M loss from a +$38.6M profit due to $104.4M in impairments. Adjusted EBITDA margin contracted 300 bps, and the company revised 2026 guidance downward. The Avis and Hertz contract renewals on less favorable terms are a major red flag

  • LegalZoom ↓ (BEARISH)
    ▲

    Revenue grew 7% YoY, but full-year guidance was cut from $810M-$830M to $795M-$805M. The company announced a 13% workforce reduction, and business formations declined 5% YoY. The shift away from traditional search is a structural headwind

  • LifeMD ↓ (BEARISH)
    ▲

    Revenue declined 4% YoY, and Adjusted EBITDA swung from +$3.9M to -$3.5M. Full-year guidance was slashed from $220M-$230M to $205.5M-$212.5M. The transition from compounded to branded GLP-1s is proving costly and disruptive

  • Eton Pharmaceuticals ↓ (BULLISH)
    ▲

    Licensed ASN-001 with strong Phase II/III data (56% efficacy vs 15% placebo) and patent protection through 2044. NDA submission expected in 2H 2027 with a potential 2028 launch targeting 20,000-30,000 patients annually. High-risk/high-reward biotech play

  • Akebia Therapeutics ↓
    ▲

    Vafseo revenue grew 34% sequentially to $21.3M, with active patients up 41% to 10,500. However, total revenue declined 21.4% due to generic competition for Auryxia. The Vafseo ramp is promising, but the core business is eroding [BULLISH/BEARISH]

Risk Flags (10)

  • Verra Mobility / Impairment & Guidance↓ [HIGH RISK]
    ▼

    Recorded $104.4M in goodwill impairments, net income swung to a -$48.2M loss, and 2026 guidance was revised downward. Contract renewals with Avis and Hertz on less favorable terms signal structural challenges in the Parking Solutions segment

  • LegalZoom / Structural Headwind↓ [HIGH RISK]
    ▼

    Full-year 2026 revenue guidance cut by 3% to $795M-$805M, citing an industry-wide shift in customer discovery away from traditional search. A 13% workforce reduction and declining business formations (-5% YoY) indicate a fundamental business model challenge

  • LifeMD / Guidance Cut & Profitability Collapse↓ [HIGH RISK]
    ▼

    Full-year 2026 revenue guidance slashed by 7% and Adjusted EBITDA guidance cut from $12M-$17M to -$6M-$0. The transition to branded GLP-1s is destroying profitability, with Adjusted EBITDA swinging from +$3.9M to -$3.5M in Q2

  • Labcorp / Cash Burn↓ [MEDIUM RISK]
    ▼

    Cash and cash equivalents collapsed from $532.3M to $141.8M in six months, driven by $427.9M in acquisitions and $451.8M in share repurchases. The aggressive capital allocation is depleting the balance sheet

  • Iron Mountain / Leverage & Equity Deficit↓ [MEDIUM RISK]
    ▼

    Total debt rose to $17.35B, and the total deficit equity deepened to -$955M from -$709M. While revenue is growing, the capital structure is becoming increasingly risky

  • Schrodinger / Core Business Decline↓ [HIGH RISK]
    ▼

    Software revenue declined 9.7% YoY, and operating cash flow swung from +$91.9M to -$48.9M. The company's profitability is entirely dependent on non-recurring investment gains, masking a deteriorating core

  • Honest Company / Revenue Decline↓ [MEDIUM RISK]
    ▼

    Total revenue declined 10.9% YoY, with Diapers down 21.2% and Honest.com/Apparel/Canada down 83%. While profitability improved on cost cuts, the top-line erosion is a major concern

  • ZipRecruiter / Cash Burn & Non-Recurring Profit↓ [MEDIUM RISK]
    ▼

    Cash declined 31% to $129.7M, and net income was driven by a $59.3M gain on debt extinguishment. Revenue growth of only 5.2% suggests the core business is stagnating

  • Revolution Medicines / Soaring Losses↓ [MEDIUM RISK]
    ▼

    Net loss more than doubled to $644.4M from $247.8M, driven by surging R&D and G&A expenses. While the pipeline is promising, the cash burn rate is accelerating rapidly

  • MannKind / Profitability Reversal↓ [MEDIUM RISK]
    ▼

    Net income swung to a -$19.0M loss from +$0.7M, despite 43% revenue growth. SG&A expenses surged 84% to $58.3M, driven by Furoscix launch costs. The path to profitability is uncertain

Opportunities (10)

  • Eton Pharmaceuticals / ASN-001 Catalyst↓ (OPPORTUNITY)
    ◆

    Licensed a late-stage product with 56% efficacy vs 15% placebo and patent protection through 2044. NDA submission in 2H 2027 with a potential 2028 launch targeting 20,000-30,000 patients annually. The stock is a pre-revenue biotech play with a clear catalyst timeline

  • Digi International / Growth & Margin Expansion↓ (OPPORTUNITY)
    ◆

    Revenue grew 29% YoY, net income rose 54%, and gross margins expanded 130 bps to 64.8%. The company is deleveraging (debt down $51M) while growing, a rare combination

  • Warner Music Group / Streaming & Margin Expansion↓ (OPPORTUNITY)
    ◆

    Recorded Music operating margin expanded 710 bps to 21.9%, and the company is aggressively acquiring catalogs ($505M in 9M). The shift to high-margin streaming revenue is a powerful tailwind

  • Blue Bird / Micro Bird Synergy↓ (OPPORTUNITY)
    ◆

    The Micro Bird acquisition contributed $122.9M in revenue and $16.5M in Adj. EBITDA in its first quarter. The company raised full-year Adj. EBITDA guidance to ~$247M, and the Ford chassis collaboration is a long-term catalyst

  • Akebia Therapeutics / Vafseo Growth Trajectory↓ (OPPORTUNITY)
    ◆

    Vafseo revenue grew 34% sequentially, and active patients increased 41% to 10,500. If this trajectory continues, Vafseo could fully offset the decline in Auryxia from generic competition

  • Arcosa / CRH Acquisition Premium↓ (OPPORTUNITY)
    ◆

    CRH is acquiring Arcosa for $150 per share, expected to close in Q1 2027. The utility structures backlog hit a record $648.1M (+49% YTD), and aggregates margins expanded 190 bps. The acquisition provides a clear floor for the stock

  • Mativ Holdings / Turnaround & Margin Improvement↓ (OPPORTUNITY)
    ◆

    Swung to a GAAP profit of $3.6M from a -$9.5M loss, with Adjusted EBITDA up 12% and margins expanding 130 bps. Free cash flow grew 24% to $60.4M, indicating the restructuring is gaining traction

  • Digital Turbine / Operational Turnaround↓ (OPPORTUNITY)
    ◆

    Revenue grew 26.8% YoY, and the company swung to operating income of $23.1M from an operating loss of $4.7M. G&A expenses were cut 23.1%, showing disciplined cost management

  • Coca-Cola Consolidated / Volume Growth & Buyback Support↓ (OPPORTUNITY)
    ◆

    Physical case volume grew 6% YoY, and diluted EPS grew 9% to $12.60, outpacing net income growth of 7% due to share repurchases. The volume growth suggests strong consumer demand and market share gains

  • OraSure Technologies / Sequential Improvement & Cost Control↓ (OPPORTUNITY)
    ◆

    Q2 revenue grew 9.7% sequentially, and GAAP net income swung to $6.2M from a -$19.7M loss. Cash used in operations improved to $23.8M from $30.0M, suggesting the restructuring is stabilizing the business

Sector Themes (6)

  • Revenue Growth vs. Margin Compression
    ◆

    Across 10 reporting companies, 8 showed YoY revenue growth, but 5 experienced margin compression or declining profitability. This suggests that top-line growth is being achieved at the expense of pricing power or through costly investments, a pattern seen in Verra Mobility, Coca-Cola Consolidated, and MannKind.

  • Non-Recurring Gains Masking Core Weakness
    ◆

    Multiple companies (ZipRecruiter, Schrodinger, Honest Company) reported net income improvements driven by one-time gains (debt extinguishment, equity gains, contingent consideration adjustments) rather than operational improvements. Investors should look through these non-recurring items to assess underlying business health.

  • Aggressive M&A and Capital Allocation
    ◆

    Labcorp ($427.9M), Warner Music ($505M), and Blue Bird (Micro Bird) are making significant acquisitions, while Uber ($3.5B) and Labcorp ($451.8M) are aggressively buying back shares. This is straining balance sheets, as seen in Labcorp's cash collapse and Iron Mountain's deepening equity deficit.

  • Healthcare Transition Costs
    ◆

    LifeMD and MannKind are both incurring heavy costs to transition their product portfolios (LifeMD to branded GLP-1s, MannKind to Furoscix). This is creating short-term profitability headwinds but may position them for long-term growth if the transitions succeed.

  • SPAC and M&A Activity Resurgence
    ◆

    The McKinley Acquisition Corp./Space-Eyes merger ($638M valuation) and the Gentherm/Modine Reverse Morris Trust transaction signal a pickup in complex corporate structures. The Space-Eyes deal, with Eric Trump's involvement, adds a political/regulatory dimension.

  • Commodity & Industrial Cyclical Turnaround
    ◆

    Warrior Met Coal (revenue +62%, net income swing to +$159.8M) and Mativ Holdings (swung to profit) are showing strong cyclical recoveries. This contrasts with the broader margin compression theme, suggesting that commodity-linked industrials are in a different phase of the cycle.

Watch List (8)

  • China Automotive Systems↓
    👁

    Q2 2026 earnings release scheduled for August 13, 2026. The filing is a routine scheduling notice, but the results will provide insight into the Chinese auto parts market [August 13, 2026]

  • Verra Mobility↓
    👁

    The company revised 2026 guidance downward and recorded $104.4M in impairments. The next earnings call will be critical to assess whether the Parking Solutions segment can stabilize and if the Avis/Hertz contract renewals are isolated or indicative of broader customer churn [Next Earnings Call]

  • LegalZoom↓
    👁

    The 13% workforce reduction and lowered guidance suggest a restructuring. Monitor for further cost-cutting announcements and whether the shift away from traditional search stabilizes. The Q3 2026 revenue guidance of $192M-$196M (only 2% growth) will be a key test [Q3 2026 Earnings]

  • LifeMD↓
    👁

    The transition to branded GLP-1s is destroying profitability. Watch for subscriber growth trends and whether the 85% adoption of multi-month packages can offset the revenue decline. The revised guidance of $205.5M-$212.5M provides a clear benchmark [Q3 2026 Earnings]

  • McKinley Acquisition Corp / Space-Eyes↓
    👁

    The business combination is expected to close in Q4 2026. Monitor for S-4 filing, shareholder vote, and any regulatory scrutiny given Eric Trump's involvement. The $75M PIPE and $176.7M trust capital provide a strong cash position [Q4 2026]

  • Eton Pharmaceuticals / ASN-001↓
    👁

    The company expects to submit an NDA in 2H 2027 with a potential 2028 launch. Watch for the bioavailability bridging study results and any partnership announcements. The 20,000-30,000 annual patient target is a key addressable market metric [2H 2027]

  • Arcosa / CRH Acquisition↓
    👁

    The $150/share acquisition is expected to close in Q1 2027. Monitor for shareholder vote and regulatory approvals. The record utility structures backlog ($648.1M) provides visibility into near-term revenue [Q1 2027]

  • Revolution Medicines / Daraxonrasib↓
    👁

    FDA accepted NDA for pancreatic cancer, and Breakthrough Therapy Designation was granted for NSCLC. Enrollment in the Phase 3 RASolve 301 trial is expected to complete in 2026 with an initial readout in 2027. This is a high-impact binary event [2027]

Filing Analyses (50)
InMode Ltd. 6-K neutral materiality 5/10

05-08-2026

InMode Ltd. announced its second quarter 2026 financial results on August 5, 2026. The filing is a Form 6-K attaching the press release. No specific financial figures are provided in the filing itself, only the announcement of results.

Eton Pharmaceuticals, Inc. 8-K positive materiality 8/10

05-08-2026

Eton Pharmaceuticals licensed U.S. rights to ASN-001 (timolol topical gel) from Auson Pharmaceuticals, a late-stage product candidate for moderate infantile hemangiomas. Phase II/III data showed 56% (BID) and 42% (TID) elimination/near-elimination rates at week 24 vs. 15% for placebo. The company expects to submit an NDA in 2H 2027 with potential launch in 2028, targeting an estimated 20,000–30,000 annual patients. However, the product is still in development with no guaranteed approval, and the company faces risks from off-label competition and regulatory hurdles.

  • · ASN-001 has patent protection through 2044 with an additional patent application pending.
  • · Eton will run a bioavailability bridging study before NDA submission.
  • · ASN-001 is expected to be prescribed by the same healthcare professionals as HEMANGEOL, leveraging existing commercial infrastructure.
  • · The total U.S. infantile hemangioma market affects more than 100,000 infants annually.
  • · HEMANGEOL is the standard of care for systemic therapy, representing 10,000–15,000 patients annually.
WINTRUST FINANCIAL CORP 10-Q materiality 6/10

05-08-2026

China Automotive Systems, Inc. 6-K neutral materiality 2/10

05-08-2026

China Automotive Systems, Inc. (CAAS) filed a Form 6-K on August 5, 2026, announcing that it will release its unaudited 2026 first half financial results on August 13, 2026. The announcement is a routine scheduling notice and contains no financial data or performance metrics.

  • · The press release was issued on August 5, 2026, and is furnished as Exhibit 99.1 to the Form 6-K.
  • · The financial results will cover the first half of 2026 (unaudited).
Evolus, Inc. 10-Q materiality 6/10

05-08-2026

LifeMD, Inc. 10-Q materiality 6/10

05-08-2026

StoneX Group Inc. 10-Q materiality 6/10

05-08-2026

Journey Beyond Wealth, LLC 13F-HR materiality 4/10

05-08-2026

NOVANTA INC 8-K neutral materiality 3/10

05-08-2026

NOVANTA INC filed an 8-K on August 5, 2026, reporting its financial results under Item 2.02 and providing financial statements under Item 9.01. The filing discloses results of operations and financial condition for the period ended, but specific revenue, earnings, or other financial metrics are not disclosed in the provided summary. No guidance, forward-looking statements, or material events beyond routine financial results are mentioned.

  • · The filing is dated August 5, 2026, and was filed with the SEC on the same day.
  • · The filing size is 1 MB, indicating it likely contains detailed financial statements and exhibits.
  • · No specific financial metrics (revenue, earnings, EBITDA, EPS) are disclosed in the provided summary.
  • · No guidance, outlook revisions, or forward-looking statements are mentioned.
  • · No scheduled events (earnings calls, meetings) are referenced in the summary.
Seaport Entertainment Group Inc. 10-Q materiality 6/10

05-08-2026

HENNESSY ADVISORS INC 10-Q materiality 6/10

05-08-2026

Sigma Lithium Corp 6-K neutral materiality 1/10

05-08-2026

Sigma Lithium Corporation filed a Form 6-K on August 5, 2026, providing its monthly report as a foreign private issuer. The filing attaches a press release dated August 5, 2026, but no financial results are included, and there is no quantitative data in the report.

AMTECH SYSTEMS INC 4 neutral materiality 5/10

05-08-2026

President & COO Shechter Guy was awarded 25,000 Restricted Stock Units.

  • · President & COO Shechter Guy was awarded 25,000 Restricted Stock Units
Fourth Sail Capital LP 13F-HR materiality 4/10

05-08-2026

Hamilton Beach Brands Holding Co 10-Q materiality 6/10

05-08-2026

ATMOS ENERGY CORP 10-Q materiality 6/10

05-08-2026

Motorola Solutions, Inc. 10-Q materiality 6/10

05-08-2026

IRON MOUNTAIN INC 10-Q mixed materiality 8/10

05-08-2026

Iron Mountain reported strong revenue growth for Q2 2026, with total revenues of $2,029M, up 18.5% YoY from $1,712M, driven by Storage rental (+12.3%) and Service (+27.4%) segments. Net income attributable to Iron Mountain swung to a profit of $101M from a loss of $45M in Q2 2025. However, the company's total deficit equity deepened to $955M from $709M at year-end 2025, and comprehensive income attributable to Iron Mountain declined slightly to $89M from $94M in the prior-year quarter.

  • · Operating income for Q2 2026 was $373.5M, up 43.7% from $259.9M in Q2 2025.
  • · Interest expense net increased to $223.4M in Q2 2026 from $205.1M in Q2 2025.
  • · Total debt (current portion + long-term) rose to $17.35B as of June 30, 2026 from $16.43B at December 31, 2025.
  • · Cash and cash equivalents increased to $204.8M from $158.5M at year-end 2025.
  • · Accounts receivable (net) increased to $1.49B from $1.44B at December 31, 2025.
  • · Goodwill remained relatively flat at $5.27B.
  • · The company declared $530.1M in parent cash dividends during H1 2026.
  • · Diluted EPS for Q2 2026 was $0.34 vs ($0.15) in Q2 2025.
  • · Foreign currency translation adjustment was a loss of $15.0M in Q2 2026 vs a gain of $139.9M in Q2 2025.
Coca-Cola Consolidated, Inc. 8-K mixed materiality 7/10

05-08-2026

Coca-Cola Consolidated, Inc. filed an 8-K on August 5, 2026, reporting its financial results for the second quarter ended June 28, 2026. Net sales increased 4% to $1.77 billion, driven by a 6% increase in physical case volume, but gross profit margin declined 130 basis points to 36.6% due to higher input costs and unfavorable mix. Net income rose 7% to $118 million, while diluted EPS grew 9% to $12.60, supported by share repurchases.

  • · Gross profit margin declined 130 bps to 36.6% due to higher input costs and unfavorable product mix.
  • · Net income grew 7% to $118 million, while diluted EPS grew 9% to $12.60, aided by share repurchases.
  • · Physical case volume increased 6% YoY, indicating strong demand.
  • · The filing includes financial statements and exhibits (Item 9.01).
ZIPRECRUITER, INC. 10-Q mixed materiality 8/10

05-08-2026

ZIPRECRUITER, INC. reported a net income of $43.4M for Q2 2026, a significant turnaround from a net loss of $9.5M in Q2 2025, driven by a $59.3M gain on debt extinguishment. Revenue grew 5.2% YoY to $118.1M, while operating income improved to $4.1M from a loss of $6.7M. However, cash and cash equivalents declined sharply to $129.7M from $188.0M at year-end 2025, and total assets fell to $321.3M from $569.7M, primarily due to debt repurchases and share buybacks.

  • · Stock-based compensation expense declined to $15.7M in H1 2026 from $27.2M in H1 2025, a 42.2% decrease.
  • · Deferred tax assets, net fell to $59.3M as of June 30, 2026 from $75.2M at December 31, 2025.
  • · Accounts receivable, net increased slightly to $26.4M from $25.7M, with allowances rising to $2.2M from $2.0M.
  • · Goodwill remained unchanged at $8.5M.
  • · Intangible assets, net decreased to $2.4M from $3.4M.
  • · Accumulated deficit improved to ($39.7M) from ($76.6M) at year-end 2025.
  • · The company repurchased $229.7M of senior unsecured notes in H1 2026, contributing to the gain on debt extinguishment.
  • · Net cash provided by operating activities surged to $11.9M in H1 2026 from $0.6M in H1 2025.
  • · Capitalized internal-use software costs were $3.9M in H1 2026, roughly flat vs $4.0M in H1 2025.
  • · Restricted cash of $2.3M was reported as of June 30, 2026, compared to none at year-end 2025.
VERRA MOBILITY Corp 8-K mixed materiality 9/10

05-08-2026

Verra Mobility reported Q2 2026 revenue of $263.6M, up 12% YoY, driven by 20% growth in Government Solutions. However, the company recorded a net loss of $(48.2)M vs. net income of $38.6M a year ago, due to $104.4M in goodwill and intangible impairments in the Parking Solutions segment. While Adjusted EBITDA rose 5% to $110.7M, Adjusted EBITDA margin contracted from 45% to 42%, and Free Cash Flow declined 19% to $32.6M. The company also extended contracts with Avis Budget Group and Hertz on materially less favorable terms, and revised its 2026 guidance downward.

  • · Parking Solutions segment profit margin declined from 16% to 11% YoY.
  • · Government Solutions segment profit margin declined from 28% to 24% YoY.
  • · Net Leverage increased from 2.3x to 2.4x sequentially.
  • · Capital expenditures expected to be approximately $135M for 2026, primarily for camera installations and MOSAIC implementation.
  • · Change in working capital expected to be a use of cash of approximately $30M for 2026.
  • · Total interest expense, net expected to be approximately $62M for 2026.
  • · Effective tax rate for 2026 expected to be 28.0% to 29.0%.
  • · Depreciation and amortization expense expected to be approximately $120M for 2026.
  • · One of three significant Commercial Services customers issued a termination notice, later rescinded and replaced with a seven-year extension on materially less favorable terms.
  • · A second significant Commercial Services customer entered into a five-year extension on materially less favorable terms with fleet volume modulation rights.
  • · CEO David Roberts departed on June 1, 2026; Jon Keyser appointed Interim CEO.
  • · Stacey Moser appointed Chief Customer Officer on June 17, 2026.
Schrodinger, Inc. 10-Q mixed materiality 8/10

05-08-2026

Schrodinger, Inc. reported Q2 2026 net income of $5.975M, a significant turnaround from a net loss of $43.173M in Q2 2025, driven largely by a $45.868M gain from the change in fair value of equity investments. However, total revenue for Q2 2026 was $58.889M, up only 7.5% from $54.759M in the prior year period, with software products and services revenue declining 9.7% to $32.544M. For the six-month period, the company reported a net loss of $54.051M, an improvement from a $102.981M loss in H1 2025, but operating cash flow turned negative at -$48.904M compared to positive $91.865M in the prior year period.

  • · Total assets decreased 11.8% from $726.160M at Dec 31, 2025 to $640.394M at June 30, 2026.
  • · Stockholders' equity decreased 9.6% from $364.053M to $328.956M over the same period.
  • · Accumulated deficit widened from $628.806M to $682.857M.
  • · Cash and cash equivalents increased from $230.517M to $287.853M, while marketable securities decreased from $164.947M to $125.886M.
  • · Accounts receivable dropped sharply from $83.041M to $21.391M, a 74.2% decline.
  • · Deferred revenue (current) decreased from $112.853M to $104.773M, and long-term deferred revenue fell from $78.877M to $45.152M.
  • · Equity investments decreased from $73.647M to $39.052M, reflecting dispositions and fair value changes.
  • · Stock-based compensation was $17.867M in H1 2026, down from $22.201M in H1 2025.
  • · Weighted average diluted shares outstanding for Q2 2026 were 75,769,360, up from 73,427,635 in Q2 2025.
ORASURE TECHNOLOGIES INC 8-K mixed materiality 7/10

05-08-2026

OraSure Technologies reported Q2 2026 total net revenues of $30.6 million, up 9.7% sequentially but down 2% year-over-year. GAAP net income was $6.2 million, a significant improvement from a GAAP net loss of $19.7 million in Q2 2025, driven largely by a $22.6 million reduction in contingent consideration liability. However, core revenues remained flat year-over-year, and non-GAAP operating loss widened to $14.7 million from $13.2 million, indicating underlying operational challenges.

  • · GAAP operating income of $5.4M in Q2 2026 vs operating loss of $18.0M in Q2 2025, but non-GAAP operating loss widened to $14.7M from $13.2M.
  • · Cash used in operating activities was $23.8M in H1 2026, improved from $30.0M in H1 2025.
  • · Cash and cash equivalents declined to $160.6M as of June 30, 2026 from $199.3M at December 31, 2025.
  • · Company withdrew its InteliQuick CT/NG submission to FDA in July 2026 and plans a future submission.
  • · Q3 2026 revenue guidance: $29.5M to $32.5M.
  • · Non-product and services revenues declined 34% YoY in Q2 2026 to $0.9M.
Honest Company, Inc. 10-Q mixed materiality 8/10

05-08-2026

Honest Company, Inc. reported net income of $10.7M for Q2 2026, up from $3.9M in Q2 2025, driven by improved gross margins and lower operating expenses. However, total revenue declined 10.9% YoY to $83.3M, with significant drops in Diapers (-21.2%) and Honest.com/Apparel/Canada (-83.0%), partially offset by strong Wipes growth (+37.3%). The company generated $37.8M in operating cash flow in H1 2026 versus a $3.7M use in H1 2025, and repurchased $19.1M of common stock during the six-month period.

  • · Gross profit margin improved to 48.4% in Q2 2026 from 40.4% in Q2 2025.
  • · Selling, general and administrative expenses decreased 26.5% YoY to $15.0M in Q2 2026.
  • · Marketing spend increased 15.3% YoY to $14.5M in Q2 2026.
  • · Restructuring credit of $383K in Q2 2026 vs. $0 in Q2 2025.
  • · Inventories reduced 31.5% from $72.5M (Dec 2025) to $49.7M (June 2026).
  • · Company repurchased 5,575,583 shares of common stock for $19.1M in H1 2026.
  • · Operating cash flow swung from -$3.7M (H1 2025) to +$37.8M (H1 2026).
  • · Diluted EPS improved to $0.09 in Q2 2026 from $0.03 in Q2 2025.
  • · Honest.com, Apparel and Canada segment revenue collapsed from $18.3M to $3.1M in Q2, likely reflecting a strategic exit or restructuring.
LEGALZOOM.COM, INC. 8-K mixed materiality 8/10

05-08-2026

LegalZoom reported Q2 2026 revenue of $205.3M (+7% YoY), driven by subscription revenue growth of 11% to $133.4M, marking the fifth consecutive quarter of double-digit subscription growth. However, transaction revenue declined 1% YoY to $71.9M, and business formations fell 5% YoY. Net income was $5.2M (3% margin), a significant improvement from a net loss of $0.3M in Q2 2025. The company updated its full-year 2026 revenue outlook downward to $795M-$805M (from $810M-$830M), citing an industry-wide shift in customer discovery away from traditional search, while maintaining Adjusted EBITDA guidance near the prior range at $190M-$195M. The company also announced a 13% workforce reduction.

  • · The company announced a 13% workforce reduction.
  • · Q3 2026 revenue guidance of $192M-$196M implies only 2% YoY growth at the midpoint.
  • · Full-year 2026 revenue outlook was reduced from $810M-$830M to $795M-$805M.
  • · Cash and cash equivalents decreased from $203.1M (Dec 31, 2025) to $167.2M (Jun 30, 2026).
  • · Non-GAAP net income declined 3% YoY to $27.4M.
  • · Business formations declined 5% YoY to 131,000 units.
  • · Subscription units declined 3% YoY to 1.892 million.
  • · Average order value declined 2% YoY to $256.
  • · Net cash from operating activities for H1 2026 was $86.8M, down 3% from $89.8M in H1 2025.
  • · Non-GAAP net income per share (basic) was flat YoY at $0.16.
Revolution Medicines, Inc. 8-K mixed materiality 9/10

05-08-2026

Revolution Medicines reported Q2 2026 financial results with a net loss of $644.4 million, compared to a net loss of $247.8 million in Q2 2025, driven by higher R&D and G&A expenses. The company highlighted significant clinical progress, including FDA acceptance of its NDA for daraxonrasib in pancreatic cancer and encouraging early data in lung cancer. However, operating expenses surged, and the net loss more than doubled year-over-year, reflecting heavy investment in commercialization and pipeline expansion.

  • · FDA granted Breakthrough Therapy Designation to daraxonrasib for previously treated metastatic NSCLC with KRAS mutations other than G12C.
  • · Enrollment in global Phase 3 RASolve 301 trial for daraxonrasib in NSCLC expected to complete in 2026, with initial readout anticipated in 2027.
  • · Zoldonrasib combination in first-line NSCLC showed 100% disease control rate.
  • · Elironrasib combination in first-line NSCLC showed 97% disease control rate.
  • · RMC-5127 first-in-human trial ongoing, no dose-limiting toxicities as of July 20, 2026; objective responses seen at first dose level.
  • · First-in-human trial for RM-055 expected to initiate in Q4 2026.
  • · Full year 2026 GAAP operating expense guidance updated to $2.1-$2.2 billion, including $270-$290 million non-cash stock-based compensation.
  • · Company has up to $1.5 billion in additional committed capital from Royalty Pharma subject to milestones.
MANNKIND CORP 8-K mixed materiality 8/10

05-08-2026

MannKind reported Q2 2026 total revenues of $109.4M, up 43% YoY, driven by the addition of Furoscix and higher collaboration/royalty revenue. However, net loss was $19.0M vs. net income of $0.7M in Q2 2025, and Afrezza sales declined 7% YoY to $17.0M. The company achieved three key catalysts: FDA approval for Afrezza pediatric indication, FDA approval for Furoscix ReadyFlow, and positive Phase 1b data for nintedanib DPI (MNKD-201).

  • · Total revenues for six months ended June 30, 2026 were $199.5M, up 29% from $154.9M in H1 2025.
  • · Net loss for six months ended June 30, 2026 was $35.7M vs. net income of $13.8M in H1 2025.
  • · SG&A expenses for Q2 2026 increased 84% to $58.3M, driven by Furoscix promotion and launch support.
  • · R&D expenses for Q2 2026 increased 32% to $18.0M, primarily due to Furoscix ReadyFlow development and MNKD-201 costs.
  • · Cash, cash equivalents and investments totaled $111M as of June 30, 2026, down from $176.4M at December 31, 2025.
  • · Furoscix ReadyFlow expected to be commercially available in late August 2026.
  • · Phase 2 INFLO-2 study for nintedanib DPI (MNKD-201) is enrolling subjects globally.
  • · IND filing for ralinepag DPI (MNKD-1501) on track for year end 2026.
  • · Afrezza pediatric indication approved May 29, 2026 for ages 6 and older.
  • · Breakthrough T1D grant awarded for INHALE-1ST pediatric trial in newly diagnosed type 1 diabetes.
Arcosa, Inc. 8-K mixed materiality 9/10

05-08-2026

Arcosa reported Q2 2026 revenue of $658.7M, up 2% YoY, with Adjusted EBITDA up 5% to $145.9M and margin expansion of 60 bps. However, operating cash flow turned negative at -$24.7M and free cash flow was -$51.0M, down from positive prior year. The company is being acquired by CRH for $150 per share, expected to close in Q1 2027, and has suspended guidance.

  • · Utility structures backlog reached a record $648.1 million, up 49% from start of year; 71% expected to be recognized in 2026.
  • · Wind towers backlog was $537.4 million; 28% expected in 2026 and 66% in 2027.
  • · Aggregates Adjusted Cash Gross Profit Margin expanded 190 bps to 48.1%.
  • · Adjusted Segment EBITDA for Construction Products was roughly flat at $100.2 million.
  • · Engineered Structures Adjusted Segment EBITDA margin expanded 180 bps to 20.4%.
  • · Effective tax rate increased to 18.3% from 11.4% due to lower AMP tax credits and compensation-related benefits.
  • · Net Debt to Adjusted EBITDA was 1.9x.
  • · No borrowings on $700 million revolving credit facility.
  • · Special meeting for stockholder approval of CRH merger scheduled for September 4, 2026.
  • · Company suspended financial guidance due to pending merger.
LABCORP HOLDINGS INC. 10-Q mixed materiality 8/10

05-08-2026

Labcorp Holdings Inc. reported strong Q2 2026 results with revenue of $3,731.1M (up 5.8% YoY) and net earnings attributable to the company of $298.7M (up 25.6% YoY). For the six-month period, revenue grew 5.8% to $7,268.7M and net earnings rose 27.9% to $576.5M. However, cash and cash equivalents dropped sharply from $532.3M at year-end 2025 to $141.8M at June 30, 2026, driven by significant cash outflows for acquisitions ($427.9M) and share repurchases ($451.8M) in the first half of 2026. The company also recorded a large other comprehensive loss of $74.3M (net of tax) for the six months, compared to a gain of $227.0M in the prior year period, primarily due to foreign currency translation adjustments.

  • · Operating income for Q2 2026 was $451.6M, up 14.5% from $394.5M in Q2 2025.
  • · SG&A expenses remained nearly flat at $577.2M in Q2 2026 vs $579.3M in Q2 2025.
  • · Interest expense increased to $61.1M in Q2 2026 from $57.1M in Q2 2025.
  • · The company drew $750.0M from a term loan (2026 Term Loan) in H1 2026.
  • · Accounts receivable increased by $247.1M in H1 2026, compared to a $139.9M increase in H1 2025.
  • · Capital expenditures rose to $252.6M in H1 2026 from $203.9M in H1 2025.
  • · Dividends paid were $119.9M in H1 2026 vs $121.5M in H1 2025.
  • · Net cash provided by operating activities was nearly unchanged at $637.0M in H1 2026 vs $639.1M in H1 2025.
  • · Goodwill increased to $7,030.1M at June 30, 2026 from $6,789.5M at December 31, 2025.
  • · Intangible assets, net increased to $3,678.2M from $3,596.0M.
  • · Short-term borrowings and current portion of long-term debt dropped to $0.9M from $500.1M, reflecting the repayment of senior notes.
  • · Long-term debt increased to $5,857.6M from $5,084.6M.
  • · The company's effective tax rate for Q2 2026 was 22.6% vs 21.8% in Q2 2025.
LifeMD, Inc. 8-K mixed materiality 8/10

05-08-2026

LifeMD reported Q2 2026 revenue of $47.3M, within guidance but down 4% YoY from $49.0M, as the company continued its transition from compounded to branded GLP-1 therapies. Adjusted EBITDA loss of $3.5M improved 21% sequentially but was a sharp decline from positive $3.9M in Q2 2025. Gross margin expanded 280 bps to 89%, and active subscribers grew 20% YoY to 356,000. The company revised full-year 2026 guidance downward to revenue of $205.5M-$212.5M (from $220M-$230M) and adjusted EBITDA of -$6.0M to breakeven (from $12M-$17M), citing transition costs and launch expenses for XYOSTED®.

  • · Approximately 84% of Q2 2026 revenue came from recurring subscriptions.
  • · Weight Management Program subscribers grew from ~100,000 at Q1 2026 end to ~108,000 at Q2 2026 end.
  • · After a pricing change, the share of new weight management patients selecting multi-month packages increased from ~25% before the change to ~85% after it.
  • · Selling and marketing expenses declined $1.8M sequentially from Q1 2026.
  • · General and administrative expenses declined ~$2.2M sequentially from Q1 2026.
  • · Q3 2026 guidance: revenue $48M-$51M; adjusted EBITDA -$1M to +$2M.
  • · Q4 2026 guidance: revenue $60M-$64M; adjusted EBITDA $3M-$6M.
  • · The company had no debt at quarter end.
DIGI INTERNATIONAL INC 10-Q positive materiality 8/10

05-08-2026

Digi International reported strong financial results for the third quarter and first nine months of fiscal 2026, with total revenue growing 29% YoY to $138.7M in Q3 and 24% YoY to $391.9M year-to-date, driven by double-digit growth in both product and service revenue. Net income rose 54% to $15.7M in Q3 and 26% to $38.8M year-to-date. However, the company recorded a foreign currency translation loss of $0.3M in Q3 (vs. a $1.4M gain a year ago), and long-term debt was reduced by $51M from $159.2M to $108.1M, partly offset by $48.9M in cash used for acquisitions.

  • · Gross profit margin improved to 64.8% in Q3 FY2026 from 63.5% in Q3 FY2025.
  • · Operating income increased 53.4% to $22.9M in Q3 FY2026 from $14.9M in Q3 FY2025.
  • · Interest expense, net rose to $1.6M in Q3 FY2026 from $0.9M in Q3 FY2025, a 72% increase.
  • · Cash provided by operations was $110.4M for the nine months ended June 30, 2026, up 38% from $80.0M in the prior year period.
  • · The company acquired a business for $50.4M in cash during the nine months, allocating $15.9M to goodwill and $38.8M to identifiable intangible assets.
  • · Unearned revenue (deferred revenue) increased 36.4% to $55.5M from $40.7M at September 30, 2025.
  • · Stock-based compensation expense was $13.4M for the nine months, up 17.9% from $11.4M a year ago.
OFC FINANCIAL PLANNING, LLC 13F-HR neutral materiality 3/10

05-08-2026

OFC Financial Planning, LLC filed its quarterly 13F-HR report for the period ending June 30, 2026, disclosing 57 equity holdings with a total market value of approximately $112.6 million. The portfolio is heavily weighted toward large-cap U.S. equities and ETFs, with top holdings including Apple Inc. ($24.0M), Vanguard S&P 500 ETF ($17.3M), and iShares Core S&P 500 ETF ($6.9M). The filing reflects a diversified, income-oriented strategy with significant allocations to buffer and laddered ETFs from Innovator and Pacer.

  • · All 57 holdings are held with sole voting and dispositive power; no shared or non-dispositive positions reported.
  • · The portfolio includes a mix of individual equities (e.g., Apple, Microsoft, Nvidia) and a large number of ETFs, particularly from iShares, Vanguard, Pacer, and Innovator.
  • · Notable sector exposures include technology (Apple, Microsoft, Nvidia, Palantir, Palo Alto Networks), financials (JPMorgan, Citigroup), industrials (Caterpillar, Quanta Services), consumer (Amazon, Home Depot, McDonald's, Starbucks), and energy (Tortoise Energy ETF, Vistra).
  • · Gold exposure is held via iShares Gold Trust ($2.4M) and SPDR Gold Shares ($1.9M).
  • · International exposure includes iShares MSCI EAFE ETF, Vanguard FTSE Developed Markets ETF, Vanguard FTSE Emerging Markets ETF, Vanguard Total International Stock ETF, and WisdomTree Japan Hedged Equity Fund.
  • · The filing is a standard quarterly 13F-HR disclosure; no prior-period comparison data is available in this filing.
Uber Technologies, Inc 10-Q mixed materiality 9/10

05-08-2026

Uber reported Q2 2026 revenue of $14.2B, up 12% YoY, and net income attributable to Uber of $2.4B, up 77% YoY. However, for the first half of 2026, net income declined 15% to $2.7B from $3.1B in H1 2025, and operating cash flow improved only modestly. The company also increased debt and repurchased $3.5B in stock during the six-month period.

  • · Q2 2026 other income (expense), net was $1.3B income vs ($19M) expense in Q2 2025, a significant swing.
  • · H1 2026 provision for income taxes was $1.0B vs a benefit of ($260M) in H1 2025.
  • · Deferred tax assets decreased from $11.0B to $10.2B during the six-month period.
  • · Goodwill increased from $8.9B to $9.5B, likely due to acquisitions.
  • · The company had $1.6B in total return swap purchases during H1 2026.
  • · Operating lease right-of-use assets increased from $1.1B to $1.6B, with $567M in new non-cash lease obligations.
  • · Short-term debt of $2.0B was issued during H1 2026, with no short-term debt at year-end 2025.
  • · Equity method investments surged from $287M to $3.8B, partly due to a $2.5B reclassification of marketable securities.
  • · Accumulated deficit improved from ($10.6B) to ($8.0B) during the six-month period.
  • · Weighted-average diluted shares outstanding decreased from 2.125B to 2.050B YoY in Q2, reflecting buyback impact.
McKinley Acquisition Corp 8-K positive materiality 9/10

05-08-2026

McKinley Acquisition Corp. (MKLY) announced a definitive business combination agreement with Space-Eyes, Inc., a provider of AI-driven geospatial intelligence and counter-drone technology. The transaction implies a pro-forma equity valuation of $638 million for Space-Eyes, with up to $75 million in PIPE financing sourced to augment $176.7 million of trust capital. The deal is expected to close in Q4 2026, subject to shareholder and regulatory approvals, and Eric Trump has been announced as an investor and strategic adviser.

  • · The PIPE includes $5 million in senior secured convertible notes at initial closing upon S-4 filing, with proceeds held in a control account.
  • · Additional $70 million in senior secured convertible notes and warrants may be issued at subsequent closings, subject to conditions.
  • · At subsequent closing, Space-Eyes must issue shares equal to 9.9% of McKinley's outstanding common stock post-merger to PIPE buyers.
  • · Notes bear interest at 10% per annum and mature in 2031; warrants have an exercise price of $12.00 per share.
  • · The conversion price of notes is the lower of $12.00 or 120% of the last reported sale price post-business combination.
  • · The securities issued under the SPA are secured by a first-priority security interest in substantially all assets of Space-Eyes and its subsidiaries.
  • · Upon business combination, Space-Eyes notes and warrants will be exchanged for McKinley notes and warrants on materially identical terms.
  • · The combined company will be named Space-Eyes, Inc. and is expected to trade on Nasdaq under ticker CUAS.
  • · Eric Trump is announced as an investor and strategic adviser.
Mativ Holdings, Inc. 8-K mixed materiality 8/10

05-08-2026

Mativ Holdings reported Q2 2026 sales of $531.8 million, up 1.2% YoY, and swung to a GAAP profit of $3.6 million from a $9.5 million loss a year ago. Adjusted EBITDA rose 12% to $75.0 million, with margin expanding 130 bps to 14.1%, and free cash flow grew 24% to $60.4 million. However, the Filtration & Advanced Materials segment saw a slight organic sales decline of 0.1% and lower volume/mix, partially offsetting the stronger performance in Sustainable & Adhesive Solutions.

  • · GAAP EPS was $0.06 for Q2 2026 vs. a loss of $0.17 per share in Q2 2025.
  • · Adjusted EPS was $0.50 for Q2 2026.
  • · FAM segment GAAP gross profit margin was 23.6% in Q2 2026 vs. 23.9% in Q2 2025.
  • · SAS segment GAAP gross profit margin improved to 19.9% in Q2 2026 from 17.1% in Q2 2025.
  • · Unallocated adjusted EBITDA was -$10.9 million in Q2 2026 vs. -$10.2 million in Q2 2025, a $0.7 million increase in expense.
  • · Non-GAAP adjustments included $0.25 per share of purchase accounting expenses and $0.16 per share of loss on debt extinguishment.
  • · Quarterly cash dividend of $0.10 per share declared, payable September 25, 2026.
  • · Debt matures on a staggered basis through 2033.
Delta Accumulation, LLC 13F-HR neutral materiality 5/10

05-08-2026

Delta Accumulation, LLC filed its Form 13F-HR for the quarter ended June 30, 2026, disclosing a diversified portfolio of equity and option positions across major U.S. sectors. The filing shows significant option activity (both puts and calls) on many holdings, indicating a hedging or income-generation strategy, alongside direct equity stakes in companies such as Apple, Bank of America, and Meta Platforms.

  • · The filing includes 156 holdings (equities and options) as of June 30, 2026.
  • · The largest single position by market value is Bank of New York Mellon Corp. put options at $383,346,649 (2,650,900 shares).
  • · Significant option positions include: Bank of New York Mellon Corp. calls ($251,722,627), JPMorgan Chase & Co. calls and puts ($81,145,107 each), and Invesco QQQ Trust calls ($82,403,160).
  • · The portfolio includes small equity stakes in many companies (e.g., 1 share of Goldman Sachs, 2 shares of Bristol-Myers Squibb, 7 shares of General Mills), suggesting these may be residual positions or part of a broader strategy.
  • · No period-over-period comparisons are available as the filing only reports current quarter holdings.
StoneX Group Inc. 8-K mixed materiality 6/10

05-08-2026

StoneX Group Inc. filed an 8-K on August 5, 2026, reporting its financial results for the quarter ended June 30, 2026. The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). The company reported record quarterly revenues of $26.4 billion, up 16% year-over-year, and net income of $82.1 million, a 12% increase. However, operating expenses also rose 15% to $25.9 billion, and the effective tax rate increased to 24.5% from 22.1% in the prior year quarter, partially offsetting earnings growth.

  • · The filing includes press release and financial statements as exhibits under Item 9.01.
  • · No forward-looking guidance or outlook was provided in the filing.
  • · No material changes to risk factors or business segments were disclosed.
VisionWave Holdings, Inc. 8-K neutral materiality 1/10

05-08-2026

The filing is a Form 8-K submitted by VisionWave Holdings, Inc. on August 5, 2026, reporting Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). The press release contains no specific financial data, transaction details, or material events; it appears to be a voluntary disclosure of general corporate information. No quantitative metrics, guidance, or scheduled events are provided, limiting actionable investment insights.

  • · Filing size is 11 MB, suggesting exhibits may be attached but no specific content is described in the summary.
  • · Sector is not specified in the filing summary.
  • · No insider trading, beneficial ownership changes, or regulatory scrutiny flags are mentioned.
Fusion Capital, LLC 13F-HR neutral materiality 3/10

05-08-2026

Fusion Capital, LLC filed its Form 13F-HR for the period ending June 30, 2026, disclosing a portfolio of 112 equity holdings with a total market value of approximately $430.4 million. The fund's largest positions include VanEck ETF Trust IG Floating Rate ETF ($39.1M), Vanguard Specialized Funds Dividend Appreciation ETF ($23.2M), and Caterpillar Inc. ($22.1M), indicating a focus on income-oriented and industrial sectors. The filing provides a snapshot of the fund's holdings as of mid-2026, but does not include period-over-period comparisons, so performance trends cannot be assessed from this filing alone.

  • · The filing was signed by Jason Mengel, Managing Member of Fusion Capital, LLC, on August 5, 2026.
  • · All 112 holdings are listed with sole voting and dispositive power, indicating no shared or no authority positions.
  • · The portfolio includes a mix of large-cap U.S. equities, ETFs, and a few international holdings (e.g., BHP Billiton ADS, CRH PLC, Nebius Group N.V.).
  • · Notable smaller positions include Advanced Micro Devices ($1.0M), Tesla ($676.7K), and Nebius Group ($217.7K).
  • · The fund holds significant positions in income-oriented ETFs such as VanEck IG Floating Rate ETF ($39.1M) and Vanguard Dividend Appreciation ETF ($23.2M).
First Nebraska Trust Co 13F-HR neutral materiality 3/10

05-08-2026

First Nebraska Trust Co filed its Form 13F-HR for the quarter ended December 31, 2009, reporting 72 equity holdings with a total market value of approximately $178.3 million. The portfolio is heavily concentrated in large-cap U.S. equities, with top holdings including Sysco Corp ($82.1M), Exxon Mobil Corp ($5.2M), Berkshire Hathaway Inc. Cl B ($4.1M), Microsoft Corp ($4.0M), and Varian Medical Systems Inc ($4.0M). The filing reflects a diversified, value-oriented investment strategy with no period-over-period comparisons available.

  • · The filing covers the period ended December 31, 2009, but was filed on August 5, 2026, indicating a significant delay in reporting.
  • · The largest single holding is Sysco Corp at $82.1 million, representing about 46% of the total portfolio value.
  • · Other significant holdings include Exxon Mobil ($5.2M), Berkshire Hathaway Cl B ($4.1M), Microsoft ($4.0M), and Varian Medical Systems ($4.0M).
  • · The portfolio includes 72 equity positions, with a mix of large-cap U.S. stocks, a few ADRs (BP, CEMEX, Royal Dutch Shell), and some closed-end funds (Dreyfus Municipal Income, Helios Total Return, Western Asset Managed High Income).
  • · Notable holdings include Berkshire Hathaway both Class A (24 shares, $2.4M) and Class B (1,243 shares, $4.1M).
  • · The filing was made under SEC file number 028-27006 and is a live submission.
Tamar Securities, LLC 13F-HR neutral materiality 5/10

05-08-2026

Tamar Securities, LLC filed its Form 13F-HR for the quarter ended June 30, 2026, disclosing 98 equity holdings with a total market value of approximately $1.07 billion. The portfolio is concentrated in mega-cap technology and semiconductor stocks, with top positions including Qualcomm ($27.5M), Freeport-McMoRan ($31.1M), International Bancshares ($54.8M), and MercadoLibre ($37.6M). The firm holds small options positions in Amazon, Broadcom, Eli Lilly, Meta, Microsoft, NVIDIA, SPDR Gold, and Spotify, suggesting modest directional bets alongside core long holdings.

  • · Options positions held: Amazon (300 Call), Broadcom (400 Call), Eli Lilly (100 Call), Meta Platforms (100 Call), Microsoft (600 Call), NVIDIA (400 Call), SPDR Gold (400 Call), Spotify (400 Call).
  • · Spotify Technology is the second-largest single stock position at ~$23.6M, behind only Qualcomm at ~$27.5M.
  • · International Bancshares Corporation ($54.8M) is the largest single holding by market value.
  • · MercadoLibre ($37.6M), Regeneron ($23.1M), and Cadence Design ($22.2M) are among the largest non-mega-cap positions.
  • · Exposure to cryptocurrency-adjacent assets via iShares Bitcoin Trust ($587,802), iShares Ethereum Trust ($413,475), and American Bitcoin Corp. ($9,807).
  • · Sector ETF allocations include Select Sector SPDRs in Health Care, Discretionary, Energy, Financials, Industrials, Materials, and Technology.
Akebia Therapeutics, Inc. 8-K mixed materiality 8/10

05-08-2026

Akebia Therapeutics reported Q2 2026 total revenues of $49.1M, down 21.4% from $62.5M in Q2 2025, driven by a 46% decline in Auryxia revenues ($25.5M vs $47.2M) due to generic competition. However, Vafseo net product revenues grew 34% sequentially to $21.3M and 60% YoY, with over 10,500 patients on therapy. The company posted a net loss of $8.9M versus net income of $0.2M in the prior year quarter, reflecting lower revenues and higher expenses including a $1.9M restructuring charge.

  • · Vafseo net product revenues grew 34% sequentially from Q1 2026 to $21.3M in Q2 2026.
  • · Active Vafseo patients increased 41% from end of Q1 2026 to over 10,500 in Q2 2026.
  • · Total prescribers increased approximately 17% versus Q1 2026 to about 1,200.
  • · VOICE trial interim analysis (n=2,116) met predefined stopping criteria with statistically significant improved safety outcome (win odds 1.16; 95% CI 1.06, 1.28; p=0.0016), driven by reduced hospitalizations.
  • · Phase 2 basket trial of ebribafusp initiated for IgA nephropathy, lupus nephritis, and C3 glomerulopathy; initial data expected in 2027.
  • · Auryxia revenues declined 46% YoY to $25.5M due to generic competition and pricing pressure.
  • · Net loss of $8.9M in Q2 2026 vs net income of $0.2M in Q2 2025.
  • · Cash decreased $7.1M from $162.6M (March 31, 2026) to $155.5M (June 30, 2026).
  • · Company expects to refinance senior secured term loan facility.
  • · Restructuring expense of $1.9M related to commercial organization reorganization.
Warner Music Group Corp. 8-K positive materiality 8/10

05-08-2026

Warner Music Group reported strong fiscal Q3 2026 results with total revenue up 10% to $1,864 million, driven by double-digit growth in Recorded Music subscription streaming and Music Publishing. Net income swung to $200 million from a loss of $16 million in the prior-year quarter, and Adjusted OIBDA rose 16% to $433 million. However, growth was partially offset by unfavorable foreign currency exchange rates of approximately $16 million, and licensing revenue in Recorded Music remained flat (down 0.9% in constant currency).

  • · Recorded Music revenue grew 9.9% to $1,488 million, with digital revenue up 9.4% and physical revenue up 15.1%.
  • · Music Publishing revenue grew 12.2% to $377 million, with digital revenue up 15.2% and streaming revenue up 14.4%.
  • · Recorded Music operating income increased 62.2% to $326 million, with operating margin up 7.1 percentage points to 21.9%.
  • · Music Publishing operating income increased 18% to $71 million, with Adjusted OIBDA up 14% to $109 million.
  • · Recorded Music licensing revenue remained flat at $111 million (down 0.9% in constant currency).
  • · Recorded Music streaming revenue grew 11.8% (10.1% in constant currency), with subscription revenue up 12.5% and ad-supported revenue up 10.0%.
  • · Music Publishing streaming revenue grew 14.4% (13.8% in constant currency).
  • · Adjusted OIBDA margin expanded 1.1 percentage points to 23.2%.
  • · Cash balance increased $100 million over prior-year quarter to $618 million.
  • · Total debt includes $303 million of subsidiary debt from Tempo Music acquisition and $363 million in loans under Beethoven JV, both nonrecourse to the Company.
  • · Capital expenditures decreased 28% to $28 million from $39 million.
  • · Top sellers in the quarter included Bruno Mars, Don Toliver, sombr, Alex Warren, and Madonna.
  • · Company reiterates 50-60% operating cash flow conversion target for FY2026 and expects high end of 150-200 basis points full-year margin expansion.
  • · Unfavorable foreign currency exchange rates impacted Adjusted OIBDA by approximately $16 million in the quarter.
Warner Music Group Corp. 10-Q positive materiality 8/10

05-08-2026

Warner Music Group reported strong financial results for the three and nine months ended June 30, 2026, with revenue growing 10.4% YoY to $1,864M in Q3 and 12.3% YoY to $5,436M in the nine-month period. Net income attributable to WMG swung to a profit of $204M in Q3 from a loss of $16M in the prior year quarter, and increased 120% to $563M for the nine months. However, cash flow from operations, while improving, was pressured by a significant increase in accounts receivable and royalty advances, and the company's accumulated other comprehensive loss deepened to $220M from $189M at year-end.

  • · Net cash used in investing activities was $674M for 9M FY2026, more than double the $273M in the prior year period, driven by $505M in acquisitions of music publishing rights and catalogs.
  • · The company issued $1,295M in Senior Term Loan A Facility and repaid $1,295M in Senior Term Loan B Facility during the nine months, along with $370M in proceeds from a Beethoven Credit Agreement.
  • · Dividends paid increased to $300M for 9M FY2026 from $283M in the prior year period, and common stock repurchases rose to $48M from $3M.
  • · Redeemable noncontrolling interest of $133M was recorded at June 30, 2026, compared to $0 at September 30, 2025, reflecting contributions from a redeemable noncontrolling interest holder.
  • · The effective tax rate was 27.5% for 9M FY2026, up from 32.0% in the prior year period.
Blue Bird Corp 8-K mixed materiality 9/10

05-08-2026

Blue Bird Corp reported strong fiscal Q3 2026 results with net sales up 29.9% YoY to $517.2M and GAAP net income surging to $185.3M from $36.5M a year ago, driven largely by a $160.5M gain from the Micro Bird acquisition. Adjusted EBITDA rose 22% to $71.4M with a 14% margin, and the company raised its full-year Adj. EBITDA guidance to ~$247M. However, legacy Blue Bird operations saw a 1.0% decline in net sales and a 7.2% drop in unit sales, partially offset by higher average selling prices, while Micro Bird contributed $122.9M in revenue and $16.5M in Adj. EBITDA. The company also announced a major collaboration with Ford to design next-generation stripped chassis and plans to acquire Detroit Chassis' Detroit Plant.

  • · Micro Bird contributed $122.9M in net sales, $17.3M in gross profit, $7.4M in net income, and $16.5M in Adjusted EBITDA in Q3 FY2026.
  • · Legacy Blue Bird operations saw a 7.2% decline in unit sales in Q3 due to timing of revenue recognition for units produced but not yet delivered.
  • · The company reported a $160.5M gain from remeasuring its previously held 50% equity stake in Micro Bird upon acquisition.
  • · A $19.6M loss was recorded from the settlement of pension benefits for most pension plan participants.
  • · FY2026 guidance raised: Net Revenue ~$1.75B and Adj. EBITDA ~$247M.
  • · Long-term 2030+ targets: Adjusted EBITDA of $500M+ on $3.3B revenue (15%+ margin).
  • · Ford collaboration and Detroit Chassis plant acquisition expected to close early 2027, with production of next-gen stripped chassis starting early 2028.
  • · Parts sales declined 1.2% YoY in Q3 but increased 1.0% in the nine-month period.
  • · Adjusted diluted EPS for Q3 was $1.28, up from $1.19 in the prior year quarter.
Santacruz Silver Mining Ltd. 6-K materiality 4/10

05-08-2026

Gentherm Inc S-4/A neutral materiality 9/10

05-08-2026

Gentherm Inc. is filing an S-4/A registration statement in connection with its merger with SpinCo, a subsidiary of Modine that will own the Performance Technologies Business. The transaction involves a Reverse Morris Trust structure, with Gentherm issuing shares to Modine shareholders and paying a $45.0 million termination fee under certain conditions. Key financial terms include a $210.0 million SpinCo Cash Distribution, a Target Net Working Capital of $227.2 million (adjustable up to $232.6 million based on revenue growth), and a threshold of 50.5% for shareholder approval.

  • · The filing is an amendment (S-4/A) to Registration No. 333-297224, filed on August 5, 2026.
  • · The Separation Agreement was dated January 29, 2026.
  • · SpinCo is a Delaware corporation and wholly owned indirect subsidiary of Modine.
  • · The SpinCo Cash Distribution is subject to adjustment as set forth in the Merger Agreement.
  • · Target Net Working Capital includes a base of $227,238,000 plus 20.2% of revenue growth over the twelve months ended November 30, 2025 ($1,123,542,585), capped at $232,589,000.
  • · The Termination Fee is $45.0 million payable by Gentherm to Modine under certain termination scenarios.
  • · The transaction is structured as a Reverse Morris Trust (RMT).
  • · A special meeting of Gentherm shareholders will be held to vote on the proposals, including the Share Issuance Proposal.
Digital Turbine, Inc. 10-Q mixed materiality 8/10

05-08-2026

Digital Turbine, Inc. reported a net loss of $11.3M for the quarter ended June 30, 2026, improving from a $14.1M net loss in the prior-year quarter. Revenue grew 26.8% YoY to $166.0M, and the company swung to operating income of $23.1M from an operating loss of $4.7M. However, total interest and other expense more than doubled to $32.1M, driven by a $10.8M unrealized loss on derivatives, and the accumulated deficit widened to $728.3M.

  • · Revenue share expense increased 22.2% YoY to $71.0M, while other direct costs of revenue rose 20.0% to $13.0M.
  • · General and administrative expenses decreased 23.1% YoY to $33.0M from $42.9M.
  • · Interest expense, net increased 29.5% YoY to $12.9M.
  • · Foreign exchange transaction gain of $0.7M vs. a loss of $0.9M in the prior year.
  • · Income tax expense of $2.3M vs. a benefit of $2.1M in the prior year.
  • · Depreciation and amortization decreased 28.0% YoY to $16.8M.
  • · Capital expenditures were $6.7M, down 12.3% YoY.
  • · Proceeds from sale of assets were $4.7M in Q1 FY27 vs. $0 in Q1 FY26.
  • · Repayment of debt obligations increased to $4.7M from $0.04M.
  • · Weighted average basic shares outstanding increased 13.2% YoY to 120.7M.
WARRIOR MET COAL, INC. 10-Q positive materiality 8/10

05-08-2026

Warrior Met Coal reported a strong turnaround for the six months ended June 30, 2026, with net income of $159.8M compared to a net loss of $2.6M in the prior-year period. Total revenues surged 62% to $968.3M, driven by a 63% increase in sales to $952.1M. However, operating cash flow improved to $120.6M from $48.5M, while the company continued to face higher costs and a decline in short-term investments.

  • · Dividends per share remained unchanged at $0.08 per quarter ($0.16 for six months) in both periods.
  • · Total inventories increased 12.3% to $264.9M from $235.9M at year-end 2025.
  • · Trade accounts receivable rose 45.1% to $263.4M from $181.6M at December 31, 2025.
  • · Capital expenditures (purchase of property, plant and equipment) decreased 24.0% to $109.1M from $143.5M in the prior-year period.
  • · Net cash used in investing activities improved to $75.7M from $172.1M, partly due to proceeds from sale of short-term investments of $33.3M.
  • · Finance lease liabilities decreased 3.5% to $81.2M from $84.2M at year-end 2025.
  • · Weighted average remaining lease term for finance leases was 60.3 months as of June 30, 2026, down from 62.0 months at December 31, 2025.
  • · The company had no borrowings under its ABL facility as of June 30, 2026 and December 31, 2025.
RGC RESOURCES INC 8-K mixed materiality 6/10

05-08-2026

RGC Resources reported Q3 FY2026 net income of $559,000 ($0.05 per diluted share), essentially flat compared to $538,000 ($0.05 per diluted share) in Q3 FY2025. Operating margin improved $757,000 due to higher non-gas base rates, but operating expenses rose by a similar amount, resulting in a nominal decline in operating earnings. For the first nine months, net income increased 5.2% to $14.2 million ($1.37 per diluted share) from $13.5 million ($1.31 per diluted share) a year earlier, driven by stronger margins and lower interest expense.

  • · Q3 FY2026 operating revenues declined 0.9% YoY to $17.1M from $17.3M.
  • · Q3 FY2026 operating income fell 2.0% to $1.17M from $1.20M.
  • · Nine-month FY2026 operating revenues increased 14.6% to $92.8M from $81.0M.
  • · Cash dividends per common share increased to $0.2175 in Q3 FY2026 from $0.2075 in Q3 FY2025.
  • · Total assets grew to $339.7M as of June 30, 2026 from $324.8M a year earlier.
  • · Long-term debt increased to $145.6M from $139.7M.
  • · CEO cited persistent inflation and the effect of an industrial customer ceasing operations as headwinds.
  • · Delivered firm volumes were steady YoY; interruptible volumes to industrial customers increased but at lower-tiered margins.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings

Start free trial Browse all digests

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US SEC Filings Daily Market Digest

August 03, 2026

US SEC Filings Daily Market Digest — August 03, 2026

July 31, 2026

US SEC Filings Daily Market Digest — July 31, 2026

July 30, 2026

US SEC Filings Daily Market Digest — July 30, 2026

July 29, 2026

US SEC Filings Daily Market Digest — July 29, 2026

🇺🇸 More from United States

View all →

August 07, 2026

US Pre-Market SEC Filings Roundup — August 07, 2026

US Pre-Market SEC Filings Roundup

August 07, 2026

USA Corporate Events Calendar — August 07, 2026

USA Corporate Events Calendar

August 07, 2026

USA Earnings Calls Schedule — August 07, 2026

USA Earnings Calls Schedule

August 07, 2026

US Merger & Acquisition SEC Filings — August 07, 2026

US Merger & Acquisition SEC Filings
← All United States digests